Repare Therapeutics Inc. (NASDAQ:RPTX) Major Shareholder Bvf Partners L. P/Il Buys 6,869 Shares

Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) major shareholder Bvf Partners L. P/Il acquired 6,869 shares of the stock in a transaction on Monday, June 6th. The stock was acquired at an average cost of $13.21 per share, for a total transaction of $90,739.49. Following the acquisition, the insider now directly owns 4,368,757 shares in the company, valued at approximately $57,711,279.97. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NASDAQ RPTX traded up $0.97 during trading hours on Monday, reaching $14.10. The company’s stock had a trading volume of 994,472 shares, compared to its average volume of 551,566. The company’s 50-day moving average is $11.10 and its two-hundred day moving average is $15.17. Repare Therapeutics Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $35.75. The stock has a market cap of $590.71 million, a PE ratio of -4.28 and a beta of 0.92.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.03. Repare Therapeutics had a negative net margin of 1,533.38% and a negative return on equity of 47.60%. As a group, equities research analysts forecast that Repare Therapeutics Inc. will post -3.37 earnings per share for the current year.

Several research firms have recently commented on RPTX. Stifel Nicolaus cut Repare Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. HC Wainwright decreased their target price on shares of Repare Therapeutics from $54.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday. Zacks Investment Research raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 12th. The Goldman Sachs Group assumed coverage on shares of Repare Therapeutics in a report on Thursday, March 17th. They set a “buy” rating and a $43.00 price objective on the stock. Finally, Piper Sandler increased their target price on shares of Repare Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Repare Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $43.13.

A number of large investors have recently made changes to their positions in RPTX. National Bank of Canada FI purchased a new position in Repare Therapeutics during the fourth quarter worth $43,000. Legal & General Group Plc increased its position in Repare Therapeutics by 55.5% during the 4th quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock worth $83,000 after purchasing an additional 1,400 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Repare Therapeutics by 9.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock worth $165,000 after purchasing an additional 1,002 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in Repare Therapeutics by 28.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after purchasing an additional 1,873 shares during the last quarter. Finally, California State Teachers Retirement System purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $198,000. Hedge funds and other institutional investors own 89.66% of the company’s stock.

About Repare Therapeutics (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

See Also

Insider Buying and Selling by Quarter for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.